Kala Pharmaceuticals

Arrow flying toward bullseye

Alcon is adding 2 more arrows to its opthalmic eye drop quiver

The buyout will let Alcon get its hands on Aerie’s marketed glaucoma and ocular hypertension meds Rhopressa and Rocklatan.

Fraiser Kansteiner Aug 23, 2022 9:24am

Eye

Kala buys time by selling eye disease drugs to Alcon for $60M

May 24, 2022 10:35am

Woman in the middle of a bathroom demolition

AbbVie puts 17-year-old Restasis brand back on TV

Apr 26, 2021 8:35am

Dry eye

Kala beefs up salesforce to roll out dry-eye med Eysuvis

Oct 30, 2020 10:17am